Lanean...
Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF
BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anti-cancer drug development. Wild-type BRAF and a variety of oncogenic BRAF mutants are dependent on dimerization of the kinase domain, w...
Gorde:
| Argitaratua izan da: | ACS Chem Biol |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6733264/ https://ncbi.nlm.nih.gov/pubmed/31243962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00191 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|